Clinical efficacy and symptom impact of Lianhua Qingwen granules combined with oseltamivir in influenza patients
流感患者联合应用连花清瘟颗粒和奥司他韦治疗的临床效果以及对症状的影响

摘要

目的 分析连花清瘟颗粒+奥司他韦联合治疗流感病人的作用效果。方法 2022年6月-2023年6月，选取流感患者80例作为研究对象，分组方法选择随机数字表法，可分为两组。单独应用奥司他韦在对照组内，以奥司他韦为基础对观察组患者内应用连花清瘟颗粒治疗。结果 治疗总有效率比较，观察组高于对照组（P＜0.05）。观察组患者缓解肌肉酸痛、咳嗽、乏力、发热的时间均较短（P<0.05）。治疗前，两组患者的B细胞吸引趋化因子‑1（BCA-1），C-反应蛋白水平对比（P＞0.05），治疗后观察组的上述两个指标都更低。结论 临床针对流感患者采用连花清瘟颗粒+奥司他韦方案治疗可获得显著效果，对病人症状具备缓解价值，同时对病人BCA-1，C-反应蛋白水平均得到更好的改善，不良反应发生率较低，值得临床推广应用。

Abstract

Objective To evaluate the therapeutic effect of combining Lianhua Qingwen granules with oseltamivir in treating influenza patients.
Methods From June 2022 to June 2023, 80 influenza patients were selected as study subjects and randomly divided into two groups using a random number table method.
Results The total effective rate was significantly higher in the observation group than in the control group (P < 0.05). The observation group showed shorter recovery times for muscle pain, cough, fatigue, and fever (P < 0.05). Before treatment, there was no significant difference in B cell‑attracting chemokine‑1 (BCA-1) and C-reactive protein levels between the two groups (P > 0.05); however, after treatment, both markers were significantly lower in the observation group.
Conclusion   The combination therapy of Lianhua Qingwen granules and oseltamivir demonstrates significant clinical benefits for influenza patients, effectively alleviating symptoms, improving BCA-1 and C-reactive protein levels, and exhibiting low adverse reaction rates. This regimen is worthy of clinical promotion and application.